Introduction {#s1}
============

Typhoid is a systemic infection caused by the bacterium *Salmonella* Typhi (*S*. Typhi) ([@bib17]; [@bib5]). With an estimated 21 million cases annually, typhoid remains a persistent global health issue ([@bib3]; [@bib16]). The symptoms of typhoid arise after the organism invades the gastrointestinal wall and enters the bloodstream ([@bib6]). Isolating the organism from the bloodstream is the mainstay of typhoid diagnostics ([@bib8]; [@bib18]), but this method lacks sensitivity and researchers are aiming to discover biomarkers that may become a more reliable and rapid approach to diagnosing disease ([@bib2]). One approach for discovering biomarkers is metabolomics, a method detecting low-molecular-weight metabolites in biological materials by mass spectrometry ([@bib9]). Our previous work demonstrated that significant and reproducible metabolite profiles could segregate *S*. Typhi cases, *Salmonella* Paratyphi A cases, and asymptomatic controls in a Nepali patient cohort ([@bib14]). Further, we found that a combination of six metabolites could define the infecting pathogen in the blood of febrile patients. These data represented a major step forward in the discovery of biomarkers with the potential to be future typhoid diagnostics. We have applied a similar approach with plasma samples collected from febrile patients in Bangladesh and Senegal to further investigate and validate our previous findings.

Results {#s2}
=======

Plasma metabolites in Bangladeshi typhoid fever patients {#s2-1}
--------------------------------------------------------

By hierarchical multivariate curve resolution, we resolved 394 peaks from the GCxGC-TOFMS data (Materials and methods) in 30 plasma samples from febrile patients in Bangladesh ([Table 1](#tbl1){ref-type="table"}); after filtering to remove low-quality peaks and metabolites with a high run order correlation we detected 236 metabolite peaks suitable for modeling. Of the detected metabolite peaks, 65/236 (27.5%) had a putative annotation, 8/236 (3.4%) had a metabolite class, 32/236 (13.6%) were of uncertain identity, and 131/236 (55.5%) were unknown ([Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}). Initial modeling of these 236 metabolites revealed one outlying sample in the fever control group, which was excluded. We applied a supervised pattern recognition approach using Orthogonal Partial Least Squares with Discriminant Analysis (OPLS-DA) to differentiate the metabolite profiles between two sample classes (culture positive typhoid patients and fever controls). This model was then used to predict the identity of the individual samples in a third sample class (clinically suspected typhoid). The OPLS-DA model provided excellent predictive power for distinguishing between culture-positive typhoid patients and fever controls in the first predictive component using 236 informative primary metabolite features (t\[1\] and tcv\[1\]) (p=0.006) ([Figure 1A](#fig1){ref-type="fig"} and [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}).10.7554/eLife.15651.002Figure 1.OPLS-DA model of plasma metabolites from a Bangladeshi cohort of patients with culture-positive typhoid and fever controls, with prediction of suspected typhoid.(**A**) OPLS-DA model generated from GCxGC-TOFMS data from the plasma of 10 patients with culture-positive typhoid and 10 fever controls using 236 metabolites. Regular (circles) and cross-validated (squares) scores for the first predictive component (t\[1\] and tcv\[1\], respectively, linked by broken line) showing a separation between culture-positive typhoid (red) and fever control samples (grey) (p=0.006). (**B**) Column plot of the predicted scores for the first predictive component (tPS\[1\]) where clinically suspected typhoid samples (n = 9) (blue columns) have been predicted into the model distinguishing between culture-positive typhoid (red) and fever control samples (grey). Plot shows five samples were more similar to the culture-positive typhoid samples and three more similar to the controls; one sample remained marginal. The blue stars identify PCR-amplification-positive samples.**DOI:** [http://dx.doi.org/10.7554/eLife.15651.002](10.7554/eLife.15651.002)10.7554/eLife.15651.003Figure 1---figure supplement 1.OPLS-DA model of urine metabolites from a Bangladeshi cohort including patients with culture-positive typhoid and fever controls, with prediction of suspected typhoid.(**A**) OPLS-DA model generated from UHPLC-Q-TOFMS data from the urine of 10 patients with culture-positive typhoid and 10 fever controls using 941 metabolites (positive ionization mode). Regular (circles) and cross-validated (squares) scores for the first predictive component (t\[1\] and tcv\[1\], respectively, linked by broken line) showing a separation between culture-positive typhoid (red) and fever control samples (grey) (p=0.025). (**B**) Column plot of the predicted scores for the first predictive component (tPS\[1\]) where culture-negative/suspected typhoid typhoid samples (n = 9) (blue columns) have been predicted into the model distinguishing between culture-positive typhoid (red) and fever control samples (grey); PCR-amplification-positive samples are identified by the blue stars.**DOI:** [http://dx.doi.org/10.7554/eLife.15651.003](10.7554/eLife.15651.003)10.7554/eLife.15651.004Table 1.Patient group metadata for the Bangladeshi cohort.**DOI:** [http://dx.doi.org/10.7554/eLife.15651.004](10.7554/eLife.15651.004)Clinical parameter\*Culture confirmed typhoid^†^ (n = 10)^¶^Suspected typhoid^‡^ (n = 9)Fever controls^§^ (n = 10)Age (years)23 (20--30)22 (16--30)46 (20--65)Sex (male)568Fever duration (days)7 (5--11)10 (6--12)5 (5--9)Abdominal pain555Diarrhoea532Constipation142Vomiting573Cough217Rash020Dysuria002Headache646Seizure000Drowsy022Bloody stool/ Melaena101Confusion/unconscious010Axillary temperature (^o^C)38.6 (38.3--39.4)38.9 (38.5--39.4)38.6 (38.3--38.9)Pulse (bpm)108 (97--114)100 (92--110)105 (86--123)Jaundice011Hepatomegaly121Splenomegaly001Hb11.9 (10.4--12.912.0 (9.6--12.1)12.6 (10.4--14.0)WBC6.6 (4.9--8.4)7.0 (4.2--8.5)14.4 (10.7--21.1)Neutrophils (%)79 (70--81)70 (63--72)80 (78--88)Lymphocytes (%)19 (15--26)25 (24--33)15 (8--18)Monocytes (%)2 (2--3)2 (2--4)2 (2--4)Eosinophils (%)1 (1--1)1 (1--2)1 (1--2)Platelets170 (160--232)180 (160--265)280 (180--320)Urea24.6 (21.4--28.0)24.1 (22.1--29.5)67.9 (21.4--81.2)Creatinine0.9 0.6--1.0)0.9 (.7--1.0)1.6 (0.8--2.4)AST101 (47--137)51 (33--199)32 (16--78)ALT93 (48--137)36 (28--105)31 (20--43)Complications\*\*204Died^††^002[^1][^2][^3][^4][^5][^6][^7]

Prediction of culture-negative/clinically suspected typhoid fever {#s2-2}
-----------------------------------------------------------------

A major challenge in diagnosing typhoid is identifying true typhoid patients but have a negative blood culture result ([@bib13]). We observed a significant overlap between the culture-negative/clinically suspected typhoid metabolite profiles with both the culture-positive group and the fever control group ([Figure 1B](#fig1){ref-type="fig"}). We used the OPLS-DA model that distinguished between the culture-positive typhoid patients and the fever controls to predict the clinically suspected typhoid samples. We found that 5/9 plasma samples had a metabolite profile indicative of culture-positive typhoid and three exhibited a greater degree of resemblance to fever controls (one indifferent) ([Figure 1B](#fig1){ref-type="fig"}). Notably, 3/5 clinically suspected typhoid samples with a metabolite profile indicative of typhoid were additionally PCR amplification positive for *S*. Typhi in blood ([Table 1](#tbl1){ref-type="table"} and [Figure 1B](#fig1){ref-type="fig"}). We also investigated potential diagnostic typhoid signatures in urine samples from the same patients using UPLC-Q-TOFMS (Materials and methods). Examination of 941 putative metabolite peaks obtained from urine using positive ionization an OPLS-DA model resulted in significantly different metabolite profiles between the *S.* Typhiculture-positive patients and the fever controls (p=0.025) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}).

Reproducible typhoid metabolite patterns in Bangladeshi and Nepali cohorts {#s2-3}
--------------------------------------------------------------------------

We next compared informative plasma metabolites of Bangladeshi *S*. Typhiculture-positive patients with the metabolites in the *S*. Typhi patients from our previous investigation in Nepal ([@bib14]). We found 99 informative metabolites in plasma from both cohorts. Comparing the direction of change and the degree of significance we identified 33 metabolites that were consistently up- or downregulated between the culture-positive *S.* Typhi patients and fever/asymptomatic controls in the two studies ([Supplementary file 1C](#SD1-data){ref-type="supplementary-material"}). Fifteen of the 33 metabolites were multivariate significant with a stricter criteria (w\*\>\|$\overline{x}$ ±SD\|) in the Bangladeshi cohort and all 33 metabolites were multivariate significant (w\*\>\|0.03\|) in the Nepali cohort. OPLS-DA models with the 15 multivariate significant metabolites resulted in significant separations between *S.* Typhiculture-positive patients and fever controls in the current study (Bangladeshi cohort) (p=0.016), and the asymptomatic controls in the previous study (Nepali cohort) (p\<0.0001) ([Figure 2](#fig2){ref-type="fig"} and [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}). Models based on all 33 correspondingly up or downregulated metabolites could also distinguish the *S.* Typhiculture-positive patients from the fever/asymptomatic controls (current study: p=0.077, previous study: p\<0.0001) ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}).10.7554/eLife.15651.005Figure 2.The identification and validation of typhoid diagnostic metabolites.OPLS-DA models generated from GCxGC-TOFMS data using 15 informative metabolites from the current study (Bangladeshi cohort) and the previous study in Nepali cohort that were consistently up- or downregulated and significantly different in a multivariate model separating culture-positive *S.* Typhi patients from controls. (**A**) Regular (circles) and cross-validated (squares) scores for the first predictive component (t\[1\] and tcv\[1\], respectively, linked by broken line) showing a separation between culture-positive typhoid (red; n = 10) and fever control samples (grey; n = 10) (p=0.016) in the Bangladeshi cohort. (**B**) Column plot of model covariance loadings (w\*\[1\]) for the first predictive component for the 15 common named metabolites in the Bangladeshi cohort, showing metabolites with a higher relative concentration in the culture-positive typhoid group in red and metabolites with a higher relative concentration in the fever control group in grey. (**C**) Regular (circles) and cross-validated (squares) scores for the first predictive component (t\[1\] and tcv\[1\], respectively, linked by broken line) showing a separation between culture-positive typhoid (red; n = 33 including eight analytical replicates) and afebrile control samples (grey; n = 32 including seven analytical replicates) (p\<0.0001) from the Nepali cohort. (**D**) Column plot of model covariance loadings (w\*\[1\]) for the first predictive component for the 15 common named metabolites in the Nepali cohort, showing metabolites with a higher relative concentration in the typhoid group in red and metabolites with a higher relative concentration in the afebrile control group in grey.**DOI:** [http://dx.doi.org/10.7554/eLife.15651.005](10.7554/eLife.15651.005)

Typhoid fever metabolites in Bangladeshi and Senegalese validation cohorts {#s2-4}
--------------------------------------------------------------------------

For further validation, we analyzed an additional 54 plasma samples from febrile patients from Bangladesh and Senegal using a different analytical technique (GC-TOFMS, methods). This validation cohort included samples from patients with confirmed typhoid and samples from patients with malaria or infections caused by other pathogens. Through an independent targeted processing approach, we detected 247 putative metabolites; after manual filtering, 104 metabolites were suitable for modeling ([Supplementary file 1D](#SD1-data){ref-type="supplementary-material"}). Initially, a three-class OPLS-DA model was obtained indicating the discrimination of typhoid samples from the two control groups (malaria and other pathogens) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}). Furthermore, a two-class OPLS-DA model for separation between typhoid and all control samples together showed significant separation for the new Bangladeshi samples (one overlapping control) and the majority of the Senegalese samples (p\<0.0001) ([Figure 3A](#fig3){ref-type="fig"} and [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}). Malaria presents with a clinical syndrome that can be indistinguishable from typhoid fever; therefore, distinguishing between the diseases using their metabolite profiles is an important diagnostic approach. The typhoid samples were compared to the malaria positive samples in a separate OPLS-DA model and showed significant separation (p=0.0001), with two overlapping Senegalese typhoid samples, potentially signifying co-infection ([Figure 3B](#fig3){ref-type="fig"} and [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}).10.7554/eLife.15651.006Figure 3.OPLS-DA models of plasma metabolites from Bangladeshi/Senegalese validation cohorts of patients with typhoid, malaria and other infections.OPLS-DA models generated from GC-TOFMS using 104 metabolites. (**A**) Column plot of the first predictive component scores, t\[1\] showing a separation of typhoid infection samples (red; n = 14) from the two control groups; malaria (light grey; n = 15) and infections caused by other bacteria/pathogens (grey; n = 25) (p\<0.0001). For the Bangladeshi samples, there is a clear separation except for one control sample behaving as a typhoid sample, there is more overlap for the Senegalese samples. (**B**) Column plot of the first predictive component scores, t\[1\] showing a separation of typhoid infection samples (red; n = 14) from malaria samples (light grey; n = 15) (p\<0.001). There is a clear separation for the Bangladeshi samples and for the Senegalese samples except two typhoid samples behaving as malaria.**DOI:** [http://dx.doi.org/10.7554/eLife.15651.006](10.7554/eLife.15651.006)10.7554/eLife.15651.007Figure 3---figure supplement 1.Three-class OPLS-DA model of GC-TOFMS data of plasma samples from a Bangladeshi/Senegalese validation cohort including patients with typhoid, malaria and other infections based on 104 metabolites.Score plot with the scores of the two first predictive component, t\[1\] (x-axis) and t\[2\] (y-axis) showing a separation of typhoid infection samples, shown in red, from the two control groups (malaria, shown in light grey, and infections caused by other bacteria/pathogens, shown in dark grey) along the first component (with some overlap) and a separation of the malaria control group from the other infections control group along the second component (with some overlap) (p=0.0035).**DOI:** [http://dx.doi.org/10.7554/eLife.15651.007](10.7554/eLife.15651.007)10.7554/eLife.15651.008Figure 3---figure supplement 2.Comparison of metabolites for three sample cohorts.The metabolite pattern separating typhoid samples from controls in the Bangladeshi/Senegalese validation cohort was compared to the corresponding metabolite patterns in the Bangladeshi cohort in the current study and the Nepali cohort in the previous study to find metabolites that were consistently up- or downregulated and multivariate significant in the three cohorts. Column plots of first predictive component scores (t\[1\]) for OPLS-DA models separating typhoid samples (red) from controls (dark grey, including a malaria group in light grey in **A**) for (**A**) GC-TOFMS data of plasma samples from the Bangladeshi/Senegalese validation cohort based on 24 significant metabolites consistently up- or downregulated in the Bangladeshi/Senegalese cohort and the Bangladeshi cohort and/or the Nepali cohort (p\<0.0001), (**B**) GCxGC-TOFMS data of plasma samples from the Bangladeshi cohort based on 13 significant metabolites consistently up- or downregulated in the Bangladeshi/Senegalese cohort and the Bangladeshi cohort (p=0.39) and (**C**) GCxGC-TOFMS data of plasma samples from the Nepali cohort based on 14 significant metabolites consistently up or downregulated in the Bangladeshi/Senegalese cohort and the Nepali cohort (p\<0.0001). Five metabolites were consistently up or downregulated in all three cohorts.**DOI:** [http://dx.doi.org/10.7554/eLife.15651.008](10.7554/eLife.15651.008)

The informative plasma metabolites from the Bangladeshi/Senegalese validation cohort were compared to the primary Bangladeshi and Nepali cohorts. We identified 49 common metabolites across all datasets. After comparing the direction of change and degree of multivariate significance, we found 24 metabolites that were consistently up- or downregulated in the Bangladeshi/Senegalese validation cohort and the Bangladeshi cohort and/or the Nepali cohort ([Supplementary file 1D](#SD1-data){ref-type="supplementary-material"}). OPLS-DA models of the consistently up- or downregulated metabolites resulted in significant separations between those with typhoid and the control samples for the Bangladeshi/Senegalese validation cohort (p\<0.0001) ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}) and for the Nepali cohort (p\<0.0001) ([Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}), the model was weaker for the primary Bangladeshi cohort (p=0.39) ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}) ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}).

Discussion {#s3}
==========

This study augments our previous findings and provides additional insight into next generation typhoid diagnostics ([@bib14]). Previously, we aimed to identify metabolite profiles that could distinguish between patients with *S*. Typhi and *S*. Paratyphi A infections. We hypothesized that metabolite profiles might differentiate clinically indistinguishable infections caused by these genetically related pathogens ([@bib4]; [@bib11]); asymptomatic individuals constituted the control group. Here, we aimed to identify *S*. Typhi metabolite profiles in different settings without *S*. Paratyphi A disease ([@bib12]). This approach was a greater challenge given a heterogeneous fever control group and a group of patients with suspected typhoid fever. We suggest this study more closely reflects a real situation given the non-specific presentation of febrile diseases. We also assessed the diagnostic potential of urine using this methodology as it is a convenient specimen ([@bib8]).

Using a validation cohort from Asia and Africa we were able to identify significant, reproducible metabolite profiles in the blood of patients with typhoid. The identified metabolites significantly discriminated *S*. Typhi*-*culture-positive individuals from patients with alternative febrile diseases, including malaria. Among patients with clinically suspected typhoid but a negative blood culture, we identified metabolite profiles consistent with the confirmed typhoid patient profiles ([@bib15]). The metabolite profiles in urine also significantly segregated the typhoid patients from the febrile controls, but did not provide the same predictions as the plasma samples for the culture-negative patients. The culturenegative clinically suspected typhoid group is challenging because of the lack of a satisfactory reference standard diagnostic test, but this innovative method allows a new approach to investigate this problematic patient group using plasma samples.

The most important finding from this study was the identification and validation of significantly variable metabolites that can identify blood culture confirmed typhoid fever patients in distinct patient cohorts (Asia and Africa) with differing control populations. At least 24 metabolites have the potential to identify typhoid fever patients in these patients. These included glycerol-3-phosphate (carbon source and precursor for phospholipid biosynthesis) ([@bib1]), stearic acid (component of liposome)([@bib7]), and linoleic acid (bactericidal activity) ([@bib20]), pyruvic acid, and creatinine. Furthermore, leucine and phenylalanine were consistently up- or downregulated between all collections.

New approaches are needed for the diagnosis of tropical febrile diseases. We have identified and validated a panel of metabolites that can identify febrile patients with typhoid. The next challenges are to corroborate these targets in larger patient numbers and incorporate into simple diagnostic test formats. This approach could be potentially expanded into other tropical febrile diseases.

Materials and methods {#s4}
=====================

To measure the systemic metabolite profiles associated with typhoid, we selected plasma and urine samples from 30 patients in a febrile disease study conducted in Chittagong, Bangladesh ([@bib12]): Ten patients had blood culture *S.* Typhi confirmed typhoid; nine patients had a clinical diagnosis of typhoid (blood culture negative ± PCR positive for *S*. Typhi); and 11 matched individuals had a febrile disease other than typhoid (fever controls) ([Table 1](#tbl1){ref-type="table"} and [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). The study sites, population and study design are described in detail in the supplementary information and are published elsewhere ([@bib12]). Validation samples included plasma samples from 54 patients from Bangladesh and Senegal with 14 patients having confirmed *S*. Typhi infection, 15 patients having malaria and 25 having an infection caused by other bacteria/pathogens ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}) ([@bib19]; [@bib10]). Chromatograms and mass spectra of the Bangladeshi plasma samples were generated and analysed as previously described by blinded operator in a random order using comprehensive two-dimensional gas chromatography with time-of-Flight Mass Spectrometry (GCxGC-TOFMS) ([@bib14]). Chromatograms and mass spectra of urine samples were generated using high-throughput ultra-performance liquid chromatography/quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOFMS). Chromatograms and mass spectra of the Bangladeshi/Senegalese validation plasma samples were generated using one-dimensional gas chromatography with time-of-flight mass spectrometry (GC-TOFMS). Acquired and processed data was analyzed using chemometrics based pattern recognition. All methods are described in detail in [Supplementary file 3](#SD3-data){ref-type="supplementary-material"}.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Reproducible diagnostic metabolites detected in the plasma and urine of typhoid fever patients\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Prabhat Jha as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Senior Editor has drafted this decision to help you prepare a revised submission.

Summary:

This aim of this study was to identify *Salmonella* Typhi specific metabolites in plasma and urine samples in order to develop a more sensitive diagnostic test for typhoid fever. The samples were from three groups of Bangladeshi patients: confirmed typhoid cases (n=10), suspected typhoid cases (n=9) and fever controls (n=10) and were analyzed by two-dimensional gas chromatography with time-of-flight mass spectrometry (plasma) or high throughput ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (urine).

This study follows up a previous one that identified serovar-specific plasma metabolites after analysis of 3 patient groups (*Salmonella* Typhi confirmed cases, n=25, *Salmonella* Paratyphi confirmed cases, n=25; afebrile controls, n=25) in Nepal. The data presented in this manuscript complements findings previously published by the team on enhancing diagnosis and surveillance of S typhi in febrile patients through a panel of metabolites. These data are very promising but the conclusions are premature given: i) the small number of samples tested, and ii) lack of information on the febrile controls -- more information needs to be provided than the fact that they had other febrile diseases.

Essential revisions:

These promising findings could be significantly strengthened through validation of the identified metabolite pattern with a larger sample size. One suggestion is to use samples collected during routine surveillance from different countries to see how predictive these metabolites are in identifying typhoid. Additionally, it will be important to include controls with infections often confused with typhoid fever such as malaria or bacteremia/septicemia caused by *Enterobacteriaceae*, in particular non-typhoidal *Salmonella* such as Typhimurium or Enteritidis (which share a same O antigen).

10.7554/eLife.15651.014

Author response

*Summary:*

*This aim of this study was to identify Salmonella Typhi specific metabolites in plasma and urine samples in order to develop a more sensitive diagnostic test for typhoid fever. The samples were from three groups of Bangladeshi patients: confirmed typhoid cases (n=10), suspected typhoid cases (n=9) and fever controls (n=10) and were analyzed by two-dimensional gas chromatography with time-of-flight mass spectrometry (plasma) or high throughput ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (urine).*

*This study follows up a previous one that identified serovar-specific plasma metabolites after analysis of 3 patient groups (Salmonella Typhi confirmed cases, n=25, Salmonella Paratyphi confirmed cases, n=25; afebrile controls, n=25) in Nepal. The data presented in this manuscript complements findings previously published by the team on enhancing diagnosis and surveillance of S typhi in febrile patients through a panel of metabolites. These data are very promising but the conclusions are premature given: i) the small number of samples tested, andii) lack of information on the febrile controls -- more information needs to be provided than the fact that they had other febrile diseases.*

*Essential revisions:*

*These promising findings could be significantly strengthened through validation of the identified metabolite pattern with a larger sample size. One suggestion is to use samples collected during routine surveillance from different countries to see how predictive these metabolites are in identifying typhoid. Additionally, it will be important to include controls with infections often confused with typhoid fever such as malaria or bacteremia/septicemia caused by Enterobacteriaceae, in particular non-typhoidal Salmonella such as Typhimurium or Enteritidis (which share a same O antigen).*

In response to the comments of the reviewers we have analysed an additional dataset including patient samples from both Bangladesh and Senegal. This validation cohort includes samples from patients with culture confirmed typhoid, patients with infection caused by other bacteria/pathogens and also a group of patients with confirmed malaria.

Changes made to the resubmitted manuscript

Title

Previous title: Reproducible diagnostic metabolites detected in the plasma and urine of typhoid fever patients

New title: Reproducible diagnostic metabolites in plasma from typhoid fever patients in Asia and Africa

Added authors

Authors associated with the Bangladeshi/Senegalese validation cohort were added

Abstract

Modification of the Abstract due to addition of Bangladeshi/Senegalese validation cohort

Introduction

Minor modification due to addition of Bangladeshi/Senegalese validation cohort

Results

Minor modifications of text in the two first paragraphs about the results of the primary Bangladeshi cohort

Removed details about urine analysis of the primary Bangladeshi cohort and moved figure to supplementary

Removed details in section about common metabolites between previous Nepali cohort and current primary Bangladeshi cohort

Added results from the Bangladeshi/Senegalese validation cohort. The results include multivariate models of all metabolites comparing typhoid samples to first all control samples then to malaria only. Metabolites from the Bangladeshi/Senegalese validation cohort were compared to the primary Bangladeshi cohort and to the previous Nepali cohort and a new set of 24 metabolites were outlined as being consistently up or down regulated in the Bangladeshi/Senegalese validation cohort and the primary Bangladeshi cohort and/or the previous Nepali cohort. Multivariate models of all three cohorts were made with these consistently regulated metabolites

Figures

[Figure 1](#fig1){ref-type="fig"} with primary Bangladeshi cohort results remains

Moved figure with result of urine analysis of the primary Bangladeshi cohort to supplementary figure (previously [Figure 2](#fig2){ref-type="fig"}, now [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"})

Changed number of figure with common metabolites between previous Nepali cohort and current primary Bangladeshi cohort (previously [Figure 3](#fig3){ref-type="fig"}, now [Figure 2](#fig2){ref-type="fig"})

Added figure of Bangladeshi/Senegalese cohort ([Figure 3](#fig3){ref-type="fig"})

Added supplementary figure of Bangladeshi/Senegalese cohort, 3-class overview model ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"})

Added supplementary figure of all three cohorts with metabolites consistently regulated in the Bangladeshi/Senegalese validation cohort and the primary Bangladeshi cohort and/or the previous Nepali cohort ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"})

Tables

[Table 1](#tbl1){ref-type="table"} with patient metadata for the primary Bangladeshi cohort remains with minor modifications

Discussion

The Bangladeshi/Senegalese validation cohort resulted in further validation of the significant metabolites differentiating culture confirmed typhoid from febrile controls (including malaria) in different patient cohorts from both Asia and Africa

Change in discussion of metabolites due to the addition of the Bangladeshi/Senegalese validation cohort

Methods

Added short description of methods for the Bangladeshi/Senegalese validation cohort

Supplementary information

Updated supplementary file with multivariate model overview ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"})

Minor changes in supplementary files with metabolite lists. Detected metabolites for primary Bangladeshi cohort ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}) and common metabolites between previous Nepali cohort and current primary Bangladeshi cohort ([Supplementary file 3](#SD3-data){ref-type="supplementary-material"})

Changed number of supplementary file with additional Materials and methods (previously Supplementary file 4, now Supplementary file 6). Also, updated with methods for Bangladeshi/Senegalese validation cohort

Added supplementary file with detected metabolites for the Bangladeshi/Senegalese validation cohort (Supplementary file 5)

Added supplementary file with patient metadata and diagnosesfor the primary Bangladeshi cohort and for the Bangladeshi/Senegalese validation cohort, as requested by the reviewers
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Change in a few references due to changed metabolites in the Discussion

All authors fulfil the criteria given in the authorship paragraph and no writing assistance was provided in the preparation of this manuscript. Our findings add new insights into typhoid diagnostics and will provide a springboard for future work into other unconventional diagnostic approaches. We think that this manuscript meets the stringent criteria of *eLife* and will be of considerable interest to your readership.

[^1]: \*Median and interquartile range (IQR) for each patient group given for quantitative parameters and number of patients with presence of symptom/characteristics for qualitative parameters.

[^2]: ^†^Typhoid confirmed by a positive blood culture for *S*. Typhi.

[^3]: ^‡^Clinical suspected typhoid fever with a negative blood culture, final diagnoses included: Clinically suspected typhoid with blood PCR amplification positive for *S*. Typhi (3); clinical suspected typhoid (4); clinical suspected typhoid or leptospirosis (1); possible typhoid encephalopathy (1).

[^4]: ^§^Fever controls included: pneumonia (3), malaria (2), meningitis (2); sepsis (1), cellulitis (1), urinary tract infection (1).

[^5]: ^¶^One sample removed from analysis due to discrepant metabolite profile.

[^6]: \*\*Complications were: gastrointestinal bleeding and severe anaemia requiring transfusion in the typhoid group; respiratory failure, hepatorenal failure, septic shock and cardiopulmonary arrest, coma and cardiopulmonary arrest, and an acute myocardial infarction in the fever controls.

[^7]: ^††^Deaths in this group were associated with sepsis and malaria.
